Abstract: A method by a rendering device includes receiving a request to render multiple surfaces corresponding to multiple virtual objects to be concurrently displayed on an augmented-reality (AR) headset. The method further includes that the AR headset is connected to the rendering device via a wireless link. In response to a determination that a network quality of the wireless link is below a threshold condition, the method further includes selecting a first subset of the multiple surfaces that are higher priority than a second subset of the plurality of surfaces. The method includes transmitting the first subset of multiple surfaces to the AR headset for display and transmitting the second subset of multiple surfaces to the AR headset for display after transmitting the first subset. This method includes rendering the surfaces in accordance with a set of rendering parameters so as to satisfy one or more network constraints.

Abstract: A method for treating hypertriglyceridemia with a composition containing wedelolactone, luteolin, and apigenin. Also provided is a method for reducing the risk of developing hypertriglyceridemia by administering the composition to a subject at risk thereof. The composition can be an extract of Wedelia chinensis.

Abstract: Compositions comprising Hirsutella sinensis mycelia extracts and chromatographically separated polysaccharide-enriched fractions thereof are provided. Methods for extracting Hirsutella sinensis mycelia are provided. Compositions for methods for their use in amelioration, prevention and treatment of sepsis, acute endotoxemia and inflammatory responses are disclosed.

Abstract: A method for treating psoriasis by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering a therapeutically effective amount of the composition to a patient in need thereof. Also disclosed is a method for treating psoriasis by first purifying Ganoderma lucidum extract into at least one fraction, then providing a pharmaceutical composition comprising at least one of the Ganoderma lucidum fractions, and administering a therapeutically effective amount of the composition to a patient in need thereof. A method for alleviating symptoms of psoriasis is disclosed. The symptoms of psoriasis are alleviated by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering an amount of the composition effective to increase at least one of an IL-10 and IL-1Ra expression, whereby the symptoms of psoriasis are ameliorated.

Abstract: Compositions comprising Hirsutella sinensis mycelia extracts and chromatographically separated polysaccharide-enriched fractions thereof are provided. Methods for extracting Hirsutella sinensis mycelia are provided. Compositions for methods for their use in amelioration, prevention and treatment of sepsis, acute endotoxemia and inflammatory responses are disclosed.

Abstract: A method for treating an allergy by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering a therapeutically effective amount of the composition to a patient in need thereof. Also disclosed is a method for treating an allergy by first purifying Ganoderma lucidum extract into at least one fraction, then providing a pharmaceutical composition comprising at least one of the Ganoderma lucidum fractions, and administering a therapeutically effective amount of the composition to a patient in need thereof. A method for alleviating symptoms of an allergy is disclosed. The symptoms of the allergy are alleviated by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering an amount of the composition effective to decrease at least one of an IgE and IgG2a level, whereby the symptoms of the allergy are ameliorated.

Abstract: A method to determine the presence or absence of Streptococcus Group A antigen in a sample, comprising the following steps: extracting the antigen from the sample in an assay chamber with two or less extraction reagents, wherein the two reagents may be added to the assay chamber in no particular sequence; introducing a lateral flow immunochromatographic assay device into the extraction reagents containing the extracted antigen without further addition of reagents or manipulation of the sample; forming an antigen-indicator labeling reagent complex; and determining the presence or absence of the antigen in the sample by the presence or absence of a signal formed by the binding of the antigen-indicator labeling reagent complex to an indicator capture reagent specific for said antigen-indicator labeling reagent complex.

Abstract: A method for treating psoriasis by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering a therapeutically effective amount of the composition to a patient in need thereof. Also disclosed is a method for treating psoriasis by first purifying Ganoderma lucidum extract into at least one fraction, then providing a pharmaceutical composition comprising at least one of the Ganoderma lucidum fractions, and administering a therapeutically effective amount of the composition to a patient in need thereof. A method for alleviating symptoms of psoriasis is disclosed. The symptoms of psoriasis are alleviated by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering an amount of the composition effective to increase at least one of an IL-10 and IL-1Ra expression, whereby the symptoms of psoriasis are ameliorated.

Abstract: A method for treating an allergy by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering a therapeutically effective amount of the composition to a patient in need thereof. Also disclosed is a method for treating an allergy by first purifying Ganoderma lucidum extract into at least one fraction, then providing a pharmaceutical composition comprising at least one of the Ganoderma lucidum fractions, and administering a therapeutically effective amount of the composition to a patient in need thereof. A method for alleviating symptoms of an allergy is disclosed. The symptoms of the allergy are alleviated by providing a pharmaceutical composition containing at least Ganoderma lucidum extract and administering an amount of the composition effective to decrease at least one of an IgE and IgG2a level, whereby the symptoms of the allergy are ameliorated.

Abstract: A method to determine the presence or absence of Streptococcus Group A antigen in a sample, comprising the following steps: extracting the antigen from the sample in an assay chamber with two or less extraction reagents, wherein the two reagents may be added to the assay chamber in no particular sequence; introducing a lateral flow immunochromatographic assay device into the extraction reagents containing the extracted antigen without further addition of reagents or manipulation of the sample; forming an antigen-indicator labeling reagent complex; and determining the presence or absence of the antigen in the sample by the presence or absence of a signal formed by the binding of the antigen-indicator labeling reagent complex to an indicator capture reagent specific for said antigen-indicator labeling reagent complex.

Abstract: A method to determine the presence or absence of Streptococcus Group A antigen in a sample, comprising the following steps: extracting the antigen from the sample in an assay chamber with two or less extraction reagents, wherein the two reagents may be added to the assay chamber in no particular sequence; introducing a lateral flow immunochromatographic assay device into the extraction reagents containing the extracted antigen without further addition of reagents or manipulation of the sample; forming an antigen-indicator labeling reagent complex; and determining the presence or absence of the antigen in the sample by the presence or absence of a signal formed by the binding of the antigen-indicator labeling reagent complex to an indicator capture reagent specific for said antigen-indicator labeling reagent complex.

Abstract: A method to determine the presence or absence of Streptococcus Group A antigen in a sample, comprising the following steps: extracting the antigen from the sample in an assay chamber with two or less extraction reagents, wherein the two reagents may be added to the assay chamber in no particular sequence; introducing a lateral flow immunochromatographic assay device into the extraction reagents containing the extracted antigen without further addition of reagents or manipulation of the sample; forming an antigen-indicator labeling reagent complex; and determining the presence or absence of the antigen in the sample by the presence or absence of a signal formed by the binding of the antigen-indicator labeling reagent complex to an indicator capture reagent specific for said antigen-indicator labeling reagent complex.

Abstract: A method to determine the presence or absence of Streptococcus Group A antigen in a sample, comprising the following steps: extracting the antigen from the sample in an assay chamber with two or less extraction reagents, wherein the two reagents may be added to the assay chamber in no particular sequence; introducing a lateral flow immunochromatographic assay device into the extraction reagents containing the extracted antigen without further addition of reagents or manipulation of the sample; forming an antigen-indicator labeling reagent complex; and determining the presence or absence of the antigen in the sample by the presence or absence of a signal formed by the binding of the antigen-indicator labeling reagent complex to an indicator capture reagent specific for said antigen-indicator labeling reagent complex.

Abstract: A device for assaying biological fluids for molecules contained therein comprising a container, material situated in the container for absorbing fluid and in communication with an antibody or antigen impregnated matrix, wherein the matrix is accessible to the exterior of the container through a funnel shaped aperture in the roof of the container. Further features include a chemical drying agent associated with the container for absorbing moisture, thereby preventing inactivation of the assay reagents, and a filter situated above the antibody or antigen impregnated matrix, and in communication with the matrix through the aperture in the roof of the container. The filter removes interfering substances present in the biological fluids, and provides protein blocking agents to the matrix material for decreasing the background of the assay.

Abstract: A device for assaying biological fluids for molecules contained therein comprising a container, material situated in the container for absorbing fluid and in communication with an antibody or antigen impregnated matrix, wherein the matrix is accessible to the exterior of the container through a funnel shaped aperture in the roof of the container. Further features include a chemical drying agent associated with the container for absorbing moisture, thereby preventing inactivation of the assay reagents, and a filter situated above the antibody or antigen impregnated matrix, and in communication with the matrix through the aperture in the roof of the container. The filter removes interfering substances present in the biological fluids, and provides protein blocking agents to the matrix material for decreasing the background of the assay.

Abstract: This invention relates to a lateral flow immunochromatographic assay device without a plastic housing. The assay includes a sample receiving region, analyte detection region and end region all made of porous material and capable of lateral flow. The analyte detection region includes labeling reagents, a capture reagent and a control reagent. The back of the porous material is laminated with a semi-rigid material with adequate mechanical strength. The top is partially covered with a thin plastic material so as to leave a portion of the sample receiving region exposed for sample application.

Abstract: A device for assaying biological fluids for molecules contained therein comprising a container, material situated in the container for absorbing fluid and in communication with an antibody or antigen impregnated matrix, wherein the matrix is accessible to the exterior of the container through a funnel shaped aperture in the roof of the container. Further features include a chemical drying agent associated with the container for absorbing moisture, thereby preventing inactivation of the assay reagents, and a filter situated above the antibody or antigen impregnated matrix, and in communication with the matrix through the aperture in the roof of the container. The filter removes interfering substances present in the biological fluids, and provides protein blocking agents to the matrix material for decreasing the background of the assay.

Abstract: This invention relates to a lateral flow immunochromatographic assay device with an increased range of sensitivity without an increase in the clearance time or the occurrence of false positive results. The indicator reagent for the analyte is located in both a separate labeling reagent region and a discrete zone of the analyte detection region.

Abstract: A device for assaying biological fluids for molecules contained therein comprising a container, material situated in the container for absorbing fluid and in communication with an antibody or antigen impregnated matrix, wherein the matrix is accessible to the exterior of the container through a funnel shaped aperture in the roof of the container. Further features include a chemical drying agent associated with the container for absorbing moisture, thereby preventing inactivation of the assay reagents, and a filter situated above the antibody or antigen impregnated matrix, and in communication with the matrix through the aperture in the roof of the container. The filter removes interfering substances present in the biological fluids and provides protein blocking agents to the matrix material for decreasing the background of the assay.

Abstract: This invention relates to a lateral flow immunochromatographic assay device without a plastic housing. The assay includes a sample receiving region, analyte detection region and end region all made of porous material and capable of lateral flow. The analyte detection region includes labeling reagents, a capture reagent and a control reagent. The back of the porous material is laminated with a semi-rigid material with adequate mechanical strength. The top is partially covered with a thin plastic material so as to leave a portion of the sample receiving region exposed for sample application.